Skinvisible, Inc. (SKVI.OB) announced that the company has signed a marketing agreement with Avani International for the company’s wholly owned division in India. This development follows Skinvisible’s recent announcement stating that the company was granted a comprehensive and exclusive patent for the company’s Invisicare product within India.
The agreement further emphasizes Skinvisible’s continued strategy to quickly expand their reach around the globe. Avani will seek additional licenses in India for the treatment of acne, fungal infections, atopic dermatitis and hand sanitizers. Furthermore, Avani will also help Skinvisible facilitate clinical studies and manufacturing logistics in this division.
Terry Howlett, President and CEO, stated, “It is important for Skinvisible to develop partnerships with companies such as Avani as they have established relationships with pharmaceutical and consumer goods companies in India. This helps us fast track our marketing efforts in the country and generate license fees and royalties quicker than marketing in India ourselves.”
Ash Chawla, Chairman & CEO of Avani, added, “India and its expanding population of over 1 billion people offers tremendous market opportunities for Skinvisible and its Invisicare technology and products. This agreement allows us to introduce Invisicare to Indian pharmaceutical manufacturers that we know need this technology.”
Let us hear your thoughts:
